Oncology and Hematology News and Journal Articles
Cancer Network presents exclusive coverage from the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2015. Below we bring you reports of the latest research, trials, scientific advances, and controversies that are changing the way gastrointestinal cancers are managed and treated.
In this interview with Dr. Roy S. Herbst, we discuss the FDA approval of nivolumab for lung cancer as well as other immunotherapies under investigation for the treatment of lung cancer.
Beta-blockers were associated with increased overall survival in women with epithelial ovarian cancer, according to a retrospective study.
A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.
A large study found that while the risk of dying from breast cancer after a DCIS diagnosis is quite low, it is on par with that of women diagnosed with small, invasive breast tumors, and that aggressive DCIS treatment does not produce better results.
The presence of the truncated form of human epidermal growth factor receptor 2 (p95HER2) in circulating tumor cells is associated with poor survival in breast cancer patients.
Treatment with the PARP inhibitor olaparib plus paclitaxel resulted in an overall survival benefit in patients with metastatic gastric cancer.
In this video, Dr. Paz-Ares discusses a phase III study that showed that nivolumab improved survival and response rates in previously treated patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
In this video, Steven I. Sherman, MD, discusses the final overall survival analysis of the EXAM study, a randomized, placebo-controlled phase III trial of cabozantinib in medullary thyroid carcinoma patients.
In this video, Dr. El-Khoueiry discusses results from a phase I/II study that suggest the PD-1 inhibitor nivolumab is safe and effective in advanced hepatocellular carcinoma.
In this video, Dr. Tap discusses a randomized phase Ib/II trial that found that adding olaratumab to doxorubicin dramatically improved survival in patients with advanced soft-tissue sarcoma.
This slide show on anaplastic thyroid carcinoma features images of cellular pleomorphism, large atypical cells, myxoid degeneration, and bizarre giant cells.